4
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0001193125-26-458247
Chief Financial Officer sold 40,000 shares at an average $30.19 ($1,207,742)
- Chief Financial Officer acquired 40,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| FRATES JAMES M Chief Financial Officer | 2026-11-09 | Option exercise 10b5-1 | +20,000 | $6.88 | $137,600 | 253,625 | D |
| FRATES JAMES M Chief Financial Officer | 2026-11-09 | Sale 10b5-1 | −7,700 | $29.39 | $226,293 | 245,925 | D |
| FRATES JAMES M Chief Financial Officer | 2026-11-09 | Sale 10b5-1 | −12,300 | $30.11 | $370,359 | 233,625 | D |
| FRATES JAMES M Chief Financial Officer | 2026-11-10 | Option exercise 10b5-1 | +20,000 | $6.88 | $137,600 | 253,625 | D |
| FRATES JAMES M Chief Financial Officer | 2026-11-10 | Sale 10b5-1 | −12,800 | $30.32 | $388,108 | 240,825 | D |
| FRATES JAMES M Chief Financial Officer | 2026-11-10 | Sale 10b5-1 | −7,200 | $30.97 | $222,983 | 233,625 | D |
| Derivatives | |||||||
| FRATES JAMES M Chief Financial Officer | 2026-11-09 | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 343,835 | D | ||
| FRATES JAMES M Chief Financial Officer | 2026-11-10 | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 323,835 | D | ||
| Open-market sales · 40,000 sh · avg $30.19 · $1,207,742 | |||||||
Loading xslF345X06/ownership.xml…